<SEC-DOCUMENT>0001737287-22-000081.txt : 20221102
<SEC-HEADER>0001737287-22-000081.hdr.sgml : 20221102
<ACCEPTANCE-DATETIME>20221102161603
ACCESSION NUMBER:		0001737287-22-000081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221102
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221102
DATE AS OF CHANGE:		20221102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		221354298

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>allo-20221102.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:24d0195e-95b8-46cb-8a82-d00e7b244706,g:f85f34de-d53f-4ca9-9a88-b1f7c270ed1b,d:5b06206d924f467babfde31a25cce119--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20221102</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV80L2ZyYWc6NDEzMmI0YmE3YTkyNGRiOGJjOTVhNmQwODg3NDJlODIvdGFibGU6OWQ4OTA4ZmNiNTRhNDJhN2JmZTQ2ODg4MDkwZTYzNjkvdGFibGVyYW5nZTo5ZDg5MDhmY2I1NGE0MmE3YmZlNDY4ODgwOTBlNjM2OV8xLTEtMS0xLTM4MzM5_4f25efff-5a86-4858-82eb-de82dcdb59b1">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV80L2ZyYWc6NDEzMmI0YmE3YTkyNGRiOGJjOTVhNmQwODg3NDJlODIvdGFibGU6OWQ4OTA4ZmNiNTRhNDJhN2JmZTQ2ODg4MDkwZTYzNjkvdGFibGVyYW5nZTo5ZDg5MDhmY2I1NGE0MmE3YmZlNDY4ODgwOTBlNjM2OV8yLTEtMS0xLTM4MzM5_bb7fbb1e-8ee7-4818-b61a-2e7890c6fddd">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20221102.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5b06206d924f467babfde31a25cce119_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDkz_68ed94e3-f706-4e06-991a-1176a241b7ee">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18yNjY_14a1f56a-06a7-4fe7-afcd-7523153b75b8">November 2, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_______________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk0_468fb91d-ef0e-4209-a8de-ad75b25da312">Allogene Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6OWVhMzRkY2FkNTQ2NDNmYjhjNGYzYmY5MGNlNjliYWIvdGFibGVyYW5nZTo5ZWEzNGRjYWQ1NDY0M2ZiOGM0ZjNiZjkwY2U2OWJhYl8wLTAtMS0xLTM4MzM5_66afdf1c-aac8-49d9-89bd-b79f4565e4ef">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6OWVhMzRkY2FkNTQ2NDNmYjhjNGYzYmY5MGNlNjliYWIvdGFibGVyYW5nZTo5ZWEzNGRjYWQ1NDY0M2ZiOGM0ZjNiZjkwY2U2OWJhYl8wLTEtMS0xLTM4MzM5_04712129-9ddd-47c9-8ed0-9870b5cd3f1b">001-38693</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6OWVhMzRkY2FkNTQ2NDNmYjhjNGYzYmY5MGNlNjliYWIvdGFibGVyYW5nZTo5ZWEzNGRjYWQ1NDY0M2ZiOGM0ZjNiZjkwY2U2OWJhYl8wLTItMS0xLTM4MzM5_211e342e-72ec-4709-9159-324c00e165b0">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDg5_616af1d2-ae36-46d4-89bb-bb760c6299fe">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk2_dbc32789-ae07-49d9-b8d3-6bc0b4f735a3">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk3_29cb9976-b768-4823-807e-2022d69579ef">California</ix:nonNumeric> <ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk4_e57fe2d6-791c-4060-9fbe-842ba6844fbb">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDky_42aeef46-c5af-4bae-ae8e-b5eb54170e8f">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDkw_ad59e95d-e55e-452c-8438-ac3b252107a7">457-2700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8wLTEtMS0xLTM4MzM5_e974104d-e103-42c8-ad7d-d549e6b88545">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8xLTEtMS0xLTM4MzM5_5a4b0a37-0e2f-46e7-b0d2-38ae6b1c37e1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8yLTEtMS0xLTM4MzM5_aa24ac0a-8670-4e8c-b18c-ec38495eeed0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8zLTEtMS0xLTM4MzM5_1fe3ef4d-ecfb-4789-b8bf-3bd414f9f212">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">on&#160;which&#160;registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MzhjYTIzMTBkODgyNGQzMmEzOTI0NWYwODc2MzE0MzAvdGFibGVyYW5nZTozOGNhMjMxMGQ4ODI0ZDMyYTM5MjQ1ZjA4NzYzMTQzMF8xLTAtMS0xLTM4MzM5_3c12ea2f-944d-4cb0-a7fd-9a7041ee833d">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MzhjYTIzMTBkODgyNGQzMmEzOTI0NWYwODc2MzE0MzAvdGFibGVyYW5nZTozOGNhMjMxMGQ4ODI0ZDMyYTM5MjQ1ZjA4NzYzMTQzMF8xLTItMS0xLTM4MzM5_59517cae-3a70-4185-b981-a74e1ca20551">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MzhjYTIzMTBkODgyNGQzMmEzOTI0NWYwODc2MzE0MzAvdGFibGVyYW5nZTozOGNhMjMxMGQ4ODI0ZDMyYTM5MjQ1ZjA4NzYzMTQzMF8xLTQtMS0xLTM4MzM5_cef37b36-c382-485e-a06c-992ea607f8d9">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b&#8211;2 of this chapter).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDkx_8e4af334-cd88-47fa-a0fd-38b6cfabad80">&#9744;</ix:nonNumeric></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i5b06206d924f467babfde31a25cce119_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;2, 2022, Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) provided a corporate update and announced its financial results for the quarter ended September&#160;30, 2022 in the press release attached hereto as Exhibit&#160;99.1, which is incorporated herein by reference.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item&#160;2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div id="i5b06206d924f467babfde31a25cce119_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20220930xexx991q322.htm">Press Release of the Company, dated November 2, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i5b06206d924f467babfde31a25cce119_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.955%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALLOGENE THERAPEUTICS, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Chang, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November 2, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>allo-20220930xexx991q322.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i89c82cf8a0fd419da39f56178eb1fbd3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt"><img alt="g725933allogenea06a.jpg" src="g725933allogenea06a.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:176px"></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&#38;D Showcase</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Initiated the Industry&#8217;s First Allogeneic CAR T Phase 2 Trial </font></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.96pt">ALPHA2 Trial, Evaluating ALLO-501A in Relapsed&#47;Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A </font></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.96pt">Readiness Activities Underway for Initiation of the EXPAND Trial, Intended to Demonstrate the Contribution of ALLO-647 to the Standard Lymphodepletion Regimen </font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Company to Host Research &#38; Development Showcase on November 29, 2022 </font></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.96pt">Event will Feature Updated Clinical Data from the CD19 and BCMA Programs </font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Ended Third Quarter with $637 Million in Cash, Cash Equivalents and Investments</font></div><div style="padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Quarterly Conference Call and Webcast Scheduled for Today at 2&#58;00 PM PT&#47;5&#58;00 PM ET</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SOUTH SAN FRANCISCO, Calif., November 2, 2022 &#8211; Allogene Therapeutics, Inc. (Nasdaq&#58; ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T&#8482;) products for cancer, today provided a corporate update and reported financial results for the quarter ended September 30, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also announced an in-person and virtual Research &#38; Development Showcase on Tuesday, November 29, 2022 in New York City. This event will discuss the Company&#8217;s CD19 program and data supporting the launch of ALPHA2, the first allogeneic CAR T Phase 2 clinical trial as well as updated data from the UNIVERSAL trial with single dose ALLO-715 and next steps for the program.  </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;We are incredibly proud of our teams and their strong execution which have enabled an industry first &#8211; the initiation of our potentially pivotal Phase 2 ALPHA2 trial,&#8221; said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. &#8220;Our leading AlloCAR T programs ALLO-501A and ALLO-715 directed at CD19 and BCMA, respectively, have made substantial progress in 2022. We look forward to providing a comprehensive update on this progress at our upcoming R&#38;D Showcase at the end of the month.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Pipeline Updates</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">CD19 Program</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene has initiated the industry&#8217;s first potentially pivotal allogeneic CAR T Phase 2 clinical trial of ALLO-501A (ALPHA2 trial) in patients with relapsed&#47;refractory (r&#47;r) large B-cell lymphoma (LBCL). The single-arm trial will utilize a single dose of ALLO-501A at 120 million CAR+ cells with a lymphodepletion regimen (FCA90) comprised of fludarabine (30 mg&#47;m2&#47;day x 3 days) and cyclophosphamide (300 mg&#47;m2&#47;day x 3 days) plus ALLO-647 (90 mg). The ALPHA2 trial will enroll approximately 100 patients who have received at least two prior lines of therapy and have not received prior anti-CD19 therapy. The primary endpoint of this trial is overall response rate (ORR) and the key secondary endpoint is duration of response (DoR). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of initiating the EXPAND trial, a separate registrational trial that is intended to demonstrate the contribution of ALLO-647 to the standard fludarabine and cyclophosphamide lymphodepletion regimen. Patients will be randomized to receive the same single 120 million cell dose of ALLO-501A as in the ALPHA2 trial and either lymphodepletion with fludarabine and cyclophosphamide alone (control arm) or the same lymphodepletion regimen of the ALPHA2 trial (active arm). The trial is expected to enroll approximately 70 patients with r&#47;r LBCL. The primary endpoint of this trial is progression free survival, and the key secondary endpoints are ORR, DoR, and the safety of ALLO-647.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene&#8217;s Alloy&#8482; manufacturing process will be deployed in the ALPHA2 and EXPAND trials. Updated clinical data from the CD19 program will be provided at the Company&#8217;s R&#38;D Showcase on November 29, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">BCMA Program</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1 UNIVERSAL trial of ALLO-715 continues enrolling patients with r&#47;r multiple myeloma (MM). The Company will provide a clinical update from UNIVERSAL focused on a single dose ALLO-715 and discuss next steps for the program at the R&#38;D Showcase. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solid Tumor Program</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALLO-316, the Company&#8217;s first AlloCAR T candidate for solid tumors, targets CD70 and is being studied in patients with advanced or metastatic clear cell renal cell carcinoma (RCC) in the Phase 1 TRAVERSE trial.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Corporate Highlights</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">CAR T Together&#8482;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company launched CAR T Together, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of off-the-shelf CAR T products to make CAR T therapy scalable and more accessible to patients with certain cancers. CAR T Together was created in response to several real-world access challenges that have emerged since the commercial introduction of autologous CAR T five years ago, highlighted by a new survey</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of U.S. based academic centers specializing in the administration of CAR T. This survey found that 82% of respondents agreed that CAR T therapies have changed how they manage aggressive cancers, but extensive wait times and manufacturing limitations keep many eligible patients from receiving treatment. Additional survey results revealed&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Only half of late-stage cancer patients who are eligible for currently FDA approved autologous CAR T therapies receive treatment.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Of those patients eligible for treatment, only 12% are able to receive treatment within one month, with approximately 40% waiting three to six months or longer to receive treatment as their disease worsens.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For eligible patients, disease progression, manufacturing capacity and comorbidities were the top barriers.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased patient demand, manufacturing capacity and time to treatment are cited by respondents as the three biggest challenges facing CAR T adoption in the future.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">CAR T Together </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">aims to support innovation and bring awareness to clinical trials that may ultimately lead to the availability of an allogeneic CAR T product for patients. Learn more at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.CARTTogether.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Allogene-Overland Biopharm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Overland Biopharm (Allogene Overland), the Company&#8217;s joint venture with Overland Pharmaceuticals, announced the completed buildout of a new, commercializable manufacturing facility in Shanghai, China. Allogene Overland is focused on the development, manufacturing and commercialization of AlloCAR T therapies for patients in greater China, Taiwan, South Korea and Singapore. The joint venture has exclusive license to develop, manufacture and commercialize specific Allogene candidates targeting BCMA, CD70, FLT3, and DLL3 in the licensed territories. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Third Quarter Financial Results</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Research and development expenses were $63.6 million for the third quarter of 2022, which includes $11.0 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">General and administrative expenses were $18.9 million for the third quarter of 2022, which includes $10.1 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">Net loss for the third quarter of 2022 was $83.1 million, or $0.58 per share, including non-cash stock-based compensation expense of $21.1 million.</font></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">The Company had $637 million in cash, cash equivalents, and investments as of September 30, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022 Financial Guidance</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company expects full year GAAP Operating Expenses to be slightly below the low end of its prior guidance of $360 million and $390 million, including estimated non-cash stock-based compensation expense of $90 million to $100 million and excluding any impact from potential business development activities. Cash burn for 2022 is expected to be less than $250 million.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call and Webcast Details</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene will host a live conference call and webcast today at 2&#58;00 p.m. Pacific Time &#47; 5&#58;00 p.m. Eastern Time to discuss financial results and provide a business update. If you would like the option to ask a question on the conference call, please use </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">this link</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to register. Upon registering for the conference call, you will receive a personal PIN to access the call, which will identify you as the participant and allow you the option to ask a question. The listen-only webcast will be made </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The survey was sponsored by Allogene Therapeutics and conducted by an independent third-party research organization. The survey did not assess the treatment status of individual patients. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">available on the Company's website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Allogene Therapeutics</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T&#8482;) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of &#8220;off-the-shelf&#8221; CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">www.allogene.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and follow &#64;AllogeneTx on Twitter and LinkedIn.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cautionary Note on Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as &#34;predicts,&#34; &#34;believes,&#34; &#34;potential,&#34; &#34;proposed,&#34; &#34;continue,&#34; &#34;estimates,&#34; &#34;anticipates,&#34; &#34;expects,&#34; &#34;plans,&#34; &#34;intends,&#34; &#34;may,&#34; &#34;could,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should&#34; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things&#58; the timing and ability to progress the ALPHA2, EXPAND, UNIVERSAL, and TRAVERSE trials, including initiating the EXPAND trial&#59; clinical outcomes, which may materially change as more patient data become available&#59; the ability to manufacture AlloCAR T&#8482; products, including with the Alloy process&#59; the ability to enroll patients in clinical trials&#59; the ability of Allogene Overland to manufacture AlloCAR T cells and initiate any clinical trials in its territories&#59;  the results from the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">CAR T Together</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> survey, which may not be representative of all CAR T treatment providers and may change as the treatment landscape evolves&#59; the potential benefits of AlloCAR T products&#59; and 2022 financial guidance. Various factors may cause material differences between Allogene&#8217;s expectations and actual results as discussed in greater detail in Allogene&#8217;s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended September 30, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AlloCAR T&#8482;, TurboCAR&#8482;, Alloy&#8482; and CAR T Together&#8482; are trademarks of Allogene Therapeutics, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TALEN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is a registered trademark of Cellectis, S.A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Allogene&#8217;s AlloCAR T&#8482; programs utilize the Cellectis TALEN&#174; technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. The anti-BCMA and anti-CD70 AlloCAR T programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these AlloCAR T programs.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i89c82cf8a0fd419da39f56178eb1fbd3_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL DATA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited&#59; in thousands, except share and per share data)</font></div><div id="i89c82cf8a0fd419da39f56178eb1fbd3_7"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENTS OF OPERATIONS</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,641&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,720&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,897&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,999&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,538&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,719&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,489)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,670)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,148)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,186)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.57)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in computing net loss per share, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,661,721&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,025,698&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i89c82cf8a0fd419da39f56178eb1fbd3_10"></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED BALANCE SHEET DATA</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and investments</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,337&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809,481&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887,572&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038,634&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,611&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739,961&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allogene Media&#47;Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christine Cassiano</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Communications Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(714) 552-0326</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Christine.Cassiano&#64;allogene.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>allo-20221102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:24d0195e-95b8-46cb-8a82-d00e7b244706,g:f85f34de-d53f-4ca9-9a88-b1f7c270ed1b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20221102" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20221102">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20221102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20221102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://allogene.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>allo-20221102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:24d0195e-95b8-46cb-8a82-d00e7b244706,g:f85f34de-d53f-4ca9-9a88-b1f7c270ed1b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_114c9228-5ead-419d-bffb-3d137783ef01_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_33b9cc64-31e2-43c1-ade7-40e98c9725d8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_28e9d695-c02b-40e3-8236-6b3c11f6b844_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_06c45ea0-0315-4fad-b6aa-b56111c83796_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8b58123f-2b7b-411a-b760-5d311f4413c2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fcbd4433-8e54-462a-812f-a4891a299cb5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_bcb5b2a9-dcb3-431d-a38d-4094a34bcf03_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8e5e4bb7-66a0-4f37-9d73-8e801497b19b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f75aa35d-ff1a-4915-bac7-7c8d42a68454_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b0b4e364-a738-4918-a547-6df7f51adac2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9a7a5b65-3d4e-4d53-81e6-c215113945ed_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1f2c320e-47bb-4840-804a-de66f474d6d7_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_20c3cc0c-b791-4f91-ae61-f34d293a5757_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d59d8716-89a5-4849-855c-b479988471a8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_12f756d9-f786-4b10-a76b-f85f8ae902cd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b13004ba-9256-45ef-97a1-c81b5c0506bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cec31b56-ee13-4c0c-891c-113026652569_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bd0630a5-ae53-40b4-b60e-afcd15f27876_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3766abe5-40b7-4b29-9c8c-c7ea13741c13_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_084b34d9-629a-427c-92ae-80a37ca9a595_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_647ff8d9-dbac-4387-98f3-7026f2c4527f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0f5bc2b6-2673-491f-85ca-109d85fd8f41_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e457471c-6ef3-4ee0-8f61-fe7fcbf105cc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>allo-20221102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:24d0195e-95b8-46cb-8a82-d00e7b244706,g:f85f34de-d53f-4ca9-9a88-b1f7c270ed1b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="allo-20221102.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6a610b8f-4dfe-41e8-b9b4-8678d0165450" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_DocumentType_6a610b8f-4dfe-41e8-b9b4-8678d0165450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d108e3a4-9e41-43b5-a8ef-81fa17364145" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_DocumentPeriodEndDate_d108e3a4-9e41-43b5-a8ef-81fa17364145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a04c1da8-41e6-47e0-a386-574dd7dc424e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityRegistrantName_a04c1da8-41e6-47e0-a386-574dd7dc424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c962451f-2e3b-4c8d-9333-fa6cd4bf038f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityCentralIndexKey_c962451f-2e3b-4c8d-9333-fa6cd4bf038f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d0e62ded-8856-4bd6-b318-346d6a063a2a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_AmendmentFlag_d0e62ded-8856-4bd6-b318-346d6a063a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_10954ba7-46e3-479d-b280-21ddf267532a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityIncorporationStateCountryCode_10954ba7-46e3-479d-b280-21ddf267532a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7c9a34cd-e0e7-4d25-89a8-dafd6d8023ba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityFileNumber_7c9a34cd-e0e7-4d25-89a8-dafd6d8023ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f54e6a17-192e-4227-984c-35e65f2a8f59" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityTaxIdentificationNumber_f54e6a17-192e-4227-984c-35e65f2a8f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_679729c5-216e-439f-924d-286c3ceaf535" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityAddressAddressLine1_679729c5-216e-439f-924d-286c3ceaf535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_16f79afc-f352-40e1-ae25-e6e5dc400faa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityAddressCityOrTown_16f79afc-f352-40e1-ae25-e6e5dc400faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f39cb80f-559e-40ac-aad8-29a914467531" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityAddressStateOrProvince_f39cb80f-559e-40ac-aad8-29a914467531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ca52cc66-f5f8-436e-8530-3fbb27d02452" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityAddressPostalZipCode_ca52cc66-f5f8-436e-8530-3fbb27d02452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_550989f0-b199-4899-bfc8-f89249f4c03f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_CityAreaCode_550989f0-b199-4899-bfc8-f89249f4c03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_68abfa41-91a6-4435-b60f-3b8bc5f6d2eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_LocalPhoneNumber_68abfa41-91a6-4435-b60f-3b8bc5f6d2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e3fc0852-5178-4c05-a629-570f17e9fb19" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_WrittenCommunications_e3fc0852-5178-4c05-a629-570f17e9fb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7cba08a5-36c2-4610-8b08-473640e92cac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_SolicitingMaterial_7cba08a5-36c2-4610-8b08-473640e92cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_74a991d9-6c6c-479c-82ec-e575f33bebe6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_PreCommencementTenderOffer_74a991d9-6c6c-479c-82ec-e575f33bebe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e98cb187-b36d-4aeb-a18e-fc2dd9626890" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e98cb187-b36d-4aeb-a18e-fc2dd9626890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5570e231-d8d2-4473-b82a-13819d46482c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_Security12bTitle_5570e231-d8d2-4473-b82a-13819d46482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_875d2fbf-0953-4dde-b40d-edee6494ad47" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_TradingSymbol_875d2fbf-0953-4dde-b40d-edee6494ad47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_53527dd5-997f-40ee-a221-ab38a6d2f579" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_SecurityExchangeName_53527dd5-997f-40ee-a221-ab38a6d2f579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3f05e2a1-1656-4653-8e02-c0976e7ec7cd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_79fcd3d5-14f6-4e17-828b-b87751f77617" xlink:to="loc_dei_EntityEmergingGrowthCompany_3f05e2a1-1656-4653-8e02-c0976e7ec7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g725933allogenea06a.jpg
<TEXT>
begin 644 g725933allogenea06a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  P ,P# 2(  A$! Q$!_\0
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M[Z7_ .AWU0_\%+#_ ,;^OV>?^O;0O_3A?5)^WC,L/_!Q/\"6;[OD:2OXF2^
M_G6U/['_ %[9PXQ_O,1_V%4_RB4_^"H!US_@H7_P5E\"_LTMJEWH_@?P^(;W
M4!:N"TTKVYNKBX*GY3(D 6&(L&\LO(P!W$5]H>*O^"-O[./B;X3R>$5^&>BZ
M7;^08H=3L%,>K6[8P)1='=(S@\_O"RD]5()%?'G_  5N\#^,/V%/^"B'@O\
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MPA^%\]QI%E8QB=EG,.P/$HB#,K7$^6DD7#-'"B[AM3'M/A^5HO\ @YYO]O\
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@]/Q^XYL3_9<:3A@:/LVY75E9*-MG[SN[];*^NU[+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140701117280880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Nov. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  02,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>allo-20221102_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="allo-20221102.xsd" xlink:type="simple"/>
    <context id="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV80L2ZyYWc6NDEzMmI0YmE3YTkyNGRiOGJjOTVhNmQwODg3NDJlODIvdGFibGU6OWQ4OTA4ZmNiNTRhNDJhN2JmZTQ2ODg4MDkwZTYzNjkvdGFibGVyYW5nZTo5ZDg5MDhmY2I1NGE0MmE3YmZlNDY4ODgwOTBlNjM2OV8xLTEtMS0xLTM4MzM5_4f25efff-5a86-4858-82eb-de82dcdb59b1">0001737287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV80L2ZyYWc6NDEzMmI0YmE3YTkyNGRiOGJjOTVhNmQwODg3NDJlODIvdGFibGU6OWQ4OTA4ZmNiNTRhNDJhN2JmZTQ2ODg4MDkwZTYzNjkvdGFibGVyYW5nZTo5ZDg5MDhmY2I1NGE0MmE3YmZlNDY4ODgwOTBlNjM2OV8yLTEtMS0xLTM4MzM5_bb7fbb1e-8ee7-4818-b61a-2e7890c6fddd">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDkz_68ed94e3-f706-4e06-991a-1176a241b7ee">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18yNjY_14a1f56a-06a7-4fe7-afcd-7523153b75b8">2022-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk0_468fb91d-ef0e-4209-a8de-ad75b25da312">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6OWVhMzRkY2FkNTQ2NDNmYjhjNGYzYmY5MGNlNjliYWIvdGFibGVyYW5nZTo5ZWEzNGRjYWQ1NDY0M2ZiOGM0ZjNiZjkwY2U2OWJhYl8wLTAtMS0xLTM4MzM5_66afdf1c-aac8-49d9-89bd-b79f4565e4ef">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6OWVhMzRkY2FkNTQ2NDNmYjhjNGYzYmY5MGNlNjliYWIvdGFibGVyYW5nZTo5ZWEzNGRjYWQ1NDY0M2ZiOGM0ZjNiZjkwY2U2OWJhYl8wLTEtMS0xLTM4MzM5_04712129-9ddd-47c9-8ed0-9870b5cd3f1b">001-38693</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6OWVhMzRkY2FkNTQ2NDNmYjhjNGYzYmY5MGNlNjliYWIvdGFibGVyYW5nZTo5ZWEzNGRjYWQ1NDY0M2ZiOGM0ZjNiZjkwY2U2OWJhYl8wLTItMS0xLTM4MzM5_211e342e-72ec-4709-9159-324c00e165b0">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDg5_616af1d2-ae36-46d4-89bb-bb760c6299fe">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk2_dbc32789-ae07-49d9-b8d3-6bc0b4f735a3">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk3_29cb9976-b768-4823-807e-2022d69579ef">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDk4_e57fe2d6-791c-4060-9fbe-842ba6844fbb">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDky_42aeef46-c5af-4bae-ae8e-b5eb54170e8f">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDkw_ad59e95d-e55e-452c-8438-ac3b252107a7">457-2700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8wLTEtMS0xLTM4MzM5_e974104d-e103-42c8-ad7d-d549e6b88545">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8xLTEtMS0xLTM4MzM5_5a4b0a37-0e2f-46e7-b0d2-38ae6b1c37e1">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8yLTEtMS0xLTM4MzM5_aa24ac0a-8670-4e8c-b18c-ec38495eeed0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MDRjMzBjMGU5MDM0NGFiNmJiMWIyMmQ5NjM5NDNmYzgvdGFibGVyYW5nZTowNGMzMGMwZTkwMzQ0YWI2YmIxYjIyZDk2Mzk0M2ZjOF8zLTEtMS0xLTM4MzM5_1fe3ef4d-ecfb-4789-b8bf-3bd414f9f212">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MzhjYTIzMTBkODgyNGQzMmEzOTI0NWYwODc2MzE0MzAvdGFibGVyYW5nZTozOGNhMjMxMGQ4ODI0ZDMyYTM5MjQ1ZjA4NzYzMTQzMF8xLTAtMS0xLTM4MzM5_3c12ea2f-944d-4cb0-a7fd-9a7041ee833d">Common&#160;Stock,&#160;$0.001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MzhjYTIzMTBkODgyNGQzMmEzOTI0NWYwODc2MzE0MzAvdGFibGVyYW5nZTozOGNhMjMxMGQ4ODI0ZDMyYTM5MjQ1ZjA4NzYzMTQzMF8xLTItMS0xLTM4MzM5_59517cae-3a70-4185-b981-a74e1ca20551">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGFibGU6MzhjYTIzMTBkODgyNGQzMmEzOTI0NWYwODc2MzE0MzAvdGFibGVyYW5nZTozOGNhMjMxMGQ4ODI0ZDMyYTM5MjQ1ZjA4NzYzMTQzMF8xLTQtMS0xLTM4MzM5_cef37b36-c382-485e-a06c-992ea607f8d9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102"
      id="id3VybDovL2RvY3MudjEvZG9jOjViMDYyMDZkOTI0ZjQ2N2JhYmZkZTMxYTI1Y2NlMTE5L3NlYzo1YjA2MjA2ZDkyNGY0NjdiYWJmZGUzMWEyNWNjZTExOV8xL2ZyYWc6YzY5MmY4OWRkYjU3NDdhZThhMzk5MjZhMzRjYWNhMjMvdGV4dHJlZ2lvbjpjNjkyZjg5ZGRiNTc0N2FlOGEzOTkyNmEzNGNhY2EyM18xNDkx_8e4af334-cd88-47fa-a0fd-38b6cfabad80">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @  ()B59>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  ""8E4+BG^.:P0  -(0   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "   @F)5GZ ;\+$"  #B#   #0              @ &M#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    (  ""8E67BKL<P    !,"   +
M  "  8D/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  ""8E4<.&7J/P$  #P"
M   /              "  7(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"   @F)5)!Z;HJT   #X 0  &@              @ '>$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "   @F)599!YDAD!  #/ P
M$P              @ '#$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="allo-20221102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="allo-20221102.htm">allo-20221102.htm</File>
    <File>allo-20220930xexx991q322.htm</File>
    <File>allo-20221102.xsd</File>
    <File>allo-20221102_lab.xml</File>
    <File>allo-20221102_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20221102.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "allo-20221102.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20221102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20221102_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20221102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20221102",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20221102.htm",
      "contextRef": "i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "role": "http://allogene.com/role/DocumentandEntityInformationDocument",
     "shortName": "Document and Entity Information Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20221102.htm",
      "contextRef": "i04b2f94f928d48efaa3daa6beb8a0b43_D20221102-20221102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://allogene.com/role/DocumentandEntityInformationDocument"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001737287-22-000081-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-22-000081-xbrl.zip
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M5JH=)CU@&)<'D7!^_NF@>7PMAB&W@5%F[!S$@V"_LJYP778^FP1C6"6[@A$
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M9__J7=]TSO4+),4CY5@XZ%B0/=JL'M(R/9"^@%\19#2D=U%FWT,K V[?CD+
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M6/TCWV)CPYXPX@!<?S (IN0YB-FR@\>7H\4&92H\JJ86;0I,#RU13L-\YN8
MY*=BR>KK[F5%OD($_5Z^*3-<*"*=@]>.6H)R.2.&X6M JOP+B5HK!>Z L9*&
M ' $PJL^&U*( Q66D \')-.J_3V+F3CJ9!S<1*%OYTD><XZ(PFR,\<,38/#A
MK1EZ37@"R4?*P<1'%)E;;)#$X-_&.AX^Y1+8E6!$7%/PMEP)W$K+CL 3%0'>
M!B\44$4LE?(3V;,J6D#<C%R#?%QF'<?1:>)FI^:X,00>XBX&&0];3Y.U2_,
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M'>DM$Z_5&YF*131_J+<K&5=G'(RGL!,ZIGP:+V>CX2H_8!IR?CJR=U4-!>;
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M-'A3N!CZN#,G?\T4Q.6OF5!38424O>BGS5W6,;+"-"X@+G]!U3\7+N&6"ZL
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MHFM*5T:HH%4V3;.2I199[\\DQONZ/FC/?V#$;_>9\9O<6<[Y<$."Z%T^I+6
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MY*R)&QHJV3A]E0L[V3CE0^:"9/.XE'-TGATHCN+:O#T/) \ ?. 'T]I_VOX
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M_?GD@7>GO0P/Q>+[<W+G_;\C/RYLJW7= 7=X_=D(K&&7CH2G?G&&03-@,"?
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MP:NV["I.Q*;PT4L'P>[_ U!+ P04    "   @F)5%8E:6G\"  ##!P  $0
M &%L;&\M,C R,C$Q,#(N>'-DS55;3]LP%'[OK_#R/.?6EB81+=)@2$C=)C$0
MO$U.?)):.'9F.[3\^\5N0R_ H-(>UI?:YWS?N1_G]&Q5<_0(2C,IIE[DAQX"
M44C*1#7U;F\N<>*=S0:#TT\8WW^YGJ,+6;0U"(/.%1 #%"V96: ["OH!E4K6
MZ$ZJ!_9(,)XYTKELGA2K%@;%81P?:E46CV@8I6/ Z3A/\.BDR'%"DAC3,(1)
M'H]&D_#D<Y65R;@<CBA@.AZ6>%20%*<D27 >E9,BGH1 H]P97>E,%PNH">H2
M$SI;Z:FW,*;)@F"Y7/K+H2]5%<1A& 7WW^8_'=3;8#D3#WOH5:YXCQ\&5IT3
M#3V<<"Z?X?92@0"_D'5@4XVB,/80,4:QO#5P*55] 25IN9EZK?C=$LY*!K0K
M-P=;T#W CMH058'Y3FK0#2G@'8>S 4*V!JQNI#)(O*#M%"%*TS18V:P\M*[9
M7!;$N$%XLP@.C^T11S$>1OY*4R_XD-M]0TQH0T0!Q_CN;KCG_8L8MAT]+H:>
M=WP,SIB&PJ_D8T"!V<Y%K[O7;\'M =O#OD\BA#2.;R4;6=,P4<JUH!/9P+,^
M^FLH^R5Y,?FOC(C[RX@JE.3OS%/0*-F ,@ST[M8X PL%Y=2STXO[J?W%2>YW
MD?20%P[V6V#504<!/M]FTG/-4]-Q==< #NO:_,^)-PJ.3;RCZ.ZY<(T^,G_+
MO^GTB-&IUS_D1-"OPC#S=-4-BJJ=W5[G(4NYO;YZ_=5Q\7S(3A]''PF%D@GF
M9C5TOPCA[:=EY]A916NS:,?NL_XT.#1WX*C50'^(F3L?5FY#WD#^0BP(+UI^
M/&\;UINTC;#OS&9S@_W57=]WUML)UF_&;/ '4$L#!!0    (  ""8E4(-2XG
M@ H  $E>   5    86QL;RTR,#(R,3$P,E]L86(N>&ULS9Q=;]LX%H;O^RNT
MWIM=8%B+$BF*19M!-],.BLVT19NB@UTL#'XI$<:1 EEIDG^_E&PG4B39)!6K
MOFD=FSY\SVL]/!0IZ?6O=U=+[X<J5FF>O9G!E_[,4YG(99I=O)E].W\/XMFO
M)R]>O/X; '_^Z\N9]ULN;JY45GJGA6*EDMYM6EYZWZ5:_>4E17[E?<^+O](?
M#("3^DNG^?5]D5Y<EE[@!\'33XM7 9(^I%@!BGD,4"0XB%D< .G[BO  (>)'
MOUR\2F*<A$@J('&8 "08!93%,> P(2(@OI*0UT&7:?;7J^H?SE;*T\EEJ_K/
M-[/+LKQ^-9_?WMZ^O./%\F5>7,P#WP_GV]:S3?.[3OO;L&X-*:7S^M.'IJNT
MKZ$."^=__G'V55RJ*P;2;%6R3%0=K-)7J_K-LURPLO9\KRYOL$7U%]@V ]5;
M  8@A"_O5G)V\L+SUG84^5)]48E7_?_MRX?!+NF\:C'/U$7URWY619K+KR4K
MRC/&U5*KKZ.5]]?JS6R57ETOU?:]RT(E_6&71=&*6JFDE4H852K_/M39?(3\
M9]);=K4^@[@ZW8_/I7&7IQ^?3>ZY'A_4X04WNADM>7U O<OD5,?N0U>CI1]>
M\7,=%GG)EA,<%H_=-"0OJS?.]*M--U6@'8-IW<]FZ&Y(57>ERJ1:CY:MT%XJ
MW\STJX54Z>)SH4[S*UWWA*J*WWGUG>)3DJAB 2$2- AB@!63 $$J 4\2#D()
M0T+B4"4^7)0/1_9"9>#;UZV(NB>3;F86698#M!9JE=\4XK'.72W[BI>N6U6E
MB^<9NU*K:[;Y@M9:30G6\D^T4B :4KVU5J\6^WK^F)RSK\N)W%H>HU&Y: E:
M5I.%O'CJ0RX,?7A$<*53J$U8*?'R(O\QUP&T&0&L7H#J14W>GK#SSJ_ZMM@J
M9H788_NFQ5SD.O1U"5J_0#6'M$FMS&T.B+6=6L#,RPO]H9[Q]B33.D3?ZE"R
M"O=^R2X68<BI$!'2DRP5 !0*")A4!"!?T5A0$F 9F]+>BGQL@#^(\RIUYD2W
M[=H/L;,)!^;6,'\K4'MS=6*S'6DR''L3:!+8W\ >NG=9F9;W;Z74/^E*GQ64
MZE/QN<A_I%KB(H@5E1'%0/@!K\@+01R$$8BXQA$F$8\1,F5P5T?'AN1:J[<1
M^XM7R]66>EO!YI3N]'<_M,_EVH$9=C?,"FL3-YPHWQEX,NA-TFN. 4;M78>$
M<W;W0>KQ)4W2]?K)QYLKKF>+?B20GH#[P \A!BC14W$>,08XCB"$(@X)C>S&
MA(&>CG10T&J]MEQOK==V3!@RV'10> ;;IAD5[!US&!3VN#%B5!B*//&PL"?!
M[KBP[POV \-7)6X*'1D&_#PMEVH1<QS#($Q P(F>'T"HAP$2^0#+4$\/$(*A
M"$S'@J?!CPW_6I27)QX,_L'_Z6WEFE/?<6\_Z&,\.3#;MG98(3V4MQ/%G6"3
M@3N41I/5P3:N=?M]NE2;2I((+A$*]:1=8010%#"@<4T 0S&%+*!4<&Q7JA^#
M'QN>FUI3"72LQPWC3$NPFQW35%T3)QSJ;#?E$:6U$6SB:MI-HUM >]K80_E=
MPUVJK%HMN\DVA7BUX)H\'C *I. A0"&4@(6QU*?8%+$0<9'XH2F9O3T<&YX;
MD5Y;I3FB_3;NYW2T.0>&U=(7*V!WYNY$;7_$R=#=F5"3W]T-[2%^LMS]8;6Z
M445S"T476(4X)R"*])DQ2D("J"15X8U]B"CAD'+'K:E.9\>&=F??9:WX>?:I
MNE9;[U:-,G#J/2L;[\9L70V:\AP;6-W@/VL;:S#-'9M9P]]QG9*_NU+%19I=
M_%[DM^6E[NN:9?>+A&#&0BQ!DNCS9D0A!IP) HB()0I8%"-LN;C>V\^Q#1>;
MZ>E6J[<6ZVW4VD[:^ZTUG;^/-FR:J;RM5P[3^IU.C)CA]\>=>+*_,[GNO']W
M<_M!X+Q@U46>7^^O>+Y<<)\C%48(,!+&%?8Q8!CIF8-,2((AD\Q\S:P5^=A
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M.3,P>&5X>#DY,7$S,C(N:'1M4$L! A0#%     @  ()B5< 1>-!L%   MX4
M !$              ( !@!P  &%L;&\M,C R,C$Q,#(N:'1M4$L! A0#%
M  @  ()B516)6EI_ @  PP<  !$              ( !&S$  &%L;&\M,C R
M,C$Q,#(N>'-D4$L! A0#%     @  ()B50@U+B> "@  25X  !4
M     ( !R3,  &%L;&\M,C R,C$Q,#)?;&%B+GAM;%!+ 0(4 Q0    (  ""
M8E6]T\^EM08  #$Q   5              "  7P^  !A;&QO+3(P,C(Q,3 R
>7W!R92YX;6Q02P4&      4 !0!. 0  9$4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
